Polyplus Transfections Inc.
Polyplus Transfections Inc., headquartered in France, is a leading innovator in the biotechnology industry, specialising in transfection solutions for gene delivery. Founded in 2001, the company has established itself as a key player in the life sciences sector, with a strong presence in Europe and North America. Polyplus is renowned for its unique range of transfection reagents and technologies, which facilitate the efficient delivery of nucleic acids into various cell types. Their flagship products, such as PEIpro® and JetPEI®, are designed to enhance research and therapeutic applications, setting them apart in a competitive market. With a commitment to advancing gene therapy and vaccine development, Polyplus has achieved significant milestones, including collaborations with major pharmaceutical companies and academic institutions. Their dedication to innovation and quality positions them as a trusted partner in the global biotechnology landscape.
DitchCarbon Score
How does Polyplus Transfections Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Polyplus Transfections Inc.'s score of 48 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Polyplus Transfections Inc.'s reported carbon emissions
In 2023, Polyplus Transfections Inc. reported total carbon emissions of approximately 13103000 kg CO2e for Scope 1, 26823000 kg CO2e for Scope 2, and 856972000 kg CO2e for Scope 3 emissions. This represents a slight decrease in Scope 1 emissions compared to 2022, where they were about 17939000 kg CO2e, and a reduction in Scope 2 emissions from approximately 28714000 kg CO2e. However, Scope 3 emissions increased from about 1091050000 kg CO2e in 2022. The breakdown of Scope 3 emissions in 2023 includes significant contributions from purchased goods and services (318901000 kg CO2e), use of sold products (185564000 kg CO2e), and upstream transportation and distribution (73625000 kg CO2e). Despite these figures, Polyplus Transfections Inc. has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction targets suggests a need for enhanced climate commitments within the industry context. As a biotechnology company, Polyplus is positioned to adopt more sustainable practices and contribute to broader climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 13,529,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 25,777,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 534,233,000 | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Polyplus Transfections Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
